GlassScriptPhysician profile
Navya Parsa
NPI 1104183011
$8,464.61
in general payments reported to CMS, 2019-2025
26 companies · $2,326 in 2025
The $2,326 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,017 · 2020: $224 · 2021: $461 · 2022: $976 · 2023: $1,609 · 2024: $1,851 · 2025: $2,326.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,731 · Education: $54.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,731.40 |
| Education | $54.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,338.08 | 2019-2025 | |
| Amgen INC. | $1,363.49 | 2019-2025 | Enbrel, Otezla, Evenity |
| Novartis Pharmaceuticals Corporation | $962.88 | 2019-2025 | |
| Janssen Biotech, INC. | $835.96 | 2019-2025 | Tremfya |
| Ucb, INC. | $408.66 | 2019-2025 | Bimzelx, Cimzia |
| Horizon Therapeutics Plc | $388.86 | 2019-2023 | Krystexxa |
| Pfizer INC. | $336.59 | 2019-2024 | |
| Genentech USA, INC. | $329.12 | 2019-2025 | Actemra, Rituxan, Enspryng |
| Astrazeneca Pharmaceuticals LP | $291.39 | 2022-2025 | Saphnelo |
| Glaxosmithkline, LLC. | $250.35 | 2021-2025 | Benlysta |
| Lilly USA, LLC | $166.61 | 2019-2025 | Taltz |
| Organon LLC | $140.40 | 2022-2025 | Hadlima, Renflexis |
| Celgene Corporation | $133.85 | 2019 | |
| Radius Health, INC. | $102.17 | 2019-2025 | Tymlos |
| Aurinia Pharma U.S., INC. | $87.22 | 2022-2024 | Lupkynis |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Octapharma USA, INC. | $71.89 | 2023-2025 | Octagam Immune Globulin (Human) |
| Fresenius Kabi USA, LLC | $56.18 | 2023-2024 | Idacio |
| Alexion Pharmaceuticals, INC. | $47.97 | 2023-2024 | Strensiq, Ultomiris |
| Sobi, INC | $30.56 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $28.21 | 2024 | Orencia |
| Antares Pharma, INC. | $18.72 | 2020 | |
| Mylan Institutional INC. | $17.99 | 2023 | Hulio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.94 | 2024 | Ofev |
| Genzyme Corporation | $14.37 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $12.67 | 2019 | |
| Mallinckrodt Hospital Products INC. | $12.48 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Navya Parsa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.